Table 1.
Experimental Protocol and Outcomes
| Chronic perforation model creation | TMs (n) | Outcome (% chronic perforations) |
|---|---|---|
| Mouse model of chronic TM perforation (model 1)—total | ||
| KB-R7785 group | 58 | 87.9% (51 of 58) |
| Saline group | 20 | 0% (0 of 20) |
| Mouse model with surgery for eustachian tube obstruction (model 2) | ||
| KB-R7785 group | 42 | 100% (42 of 42) |
| Mouse model of CSOM (model 3)—CSOM group 1 | ||
| KB-R7785 group | 16 | 100% (16 of 16) |
| Mouse model of CSOM (model 3)—CSOM group 2 | ||
| KB-R7785 group | 17 | 100% (17 of 17) |
| HB-EGF treatment of chronic perforations | Outcome (% complete closure of perforation) | |
|---|---|---|
| Mouse model of chronic TM perforation (model 1)—total | 50 | |
| Treatment group | 24 | 92% (22 of 24) |
| Control group | 26 | 38% (10 of 26) |
| Mouse model with surgery for eustachian tube obstruction (model 2) | 42 | |
| Treatment group | 19 | 94% (18 of 19) |
| Control group | 23 | 9% (2 of 23) |
| Mouse model of CSOM (model 3)—CSOM group 1 | 16 | |
| Treatment group | 8 | 100% (8 of 8) |
| Control group | 8 | 50% (4 of 8) |
| Mouse model of CSOM (model 3)—CSOM group 2 | 17 | |
| Treatment group | 8 | 100% (8 of 8) |
| Control group | 9 | 33.3% (3 of 9) |
| Mouse model of CSOM (model 3)—CSOM groups combined | 33 | |
| Treatment group | 16 | 100% (16 of 16) |
| Control group | 17 | 41% (7 of 17) |
Table shows the outcomes of the creation of the chronic perforation models as well as the HB-EGF treatment in these models.
CSOM, chronic suppurative otitis media; HB-EGF, heparin binding–epidermal growth factor; TM, tympanic membrane.